Pasteurella multocida causes a range of diseases in mammals and birds, including fowl cholera in poultry, atrophic rhinitis in pigs, and bovine hemorrhagic septicemia in cattle and buffalo. It can also cause a zoonotic infection in humans, which typically from bites or scratches from domestic pets. Many mammals (including domestic cats and dogs) and birds harbor P. multocida as part of their normal respiratory microbiota.
Pasteurella Multocida Background
Pasteurella multocida was discovered in 1878 in cholera-infected birds and then isolated in 1880 by Louis Pasteu. P. multocida is a Gram-negative, nonmotile, penicillin-sensitive coccobacillus of the family Pasteurellaceae (Kuhnert & Christensen, 2008). Strains of the species are currently classified into five serogroups (A, B, D, E, F) based on capsular composition and 16 somatic serovars (1–16).
P. multocida is a highly versatile pathogen capable of causing infections in a wide range of domestic and wild animals as well as in humans and nonhuman primates. It causes avian or fowl cholera disease; a significant disease present in commercial and domestic poultry flocks worldwide, particularly layer flocks and parent breeder flocks. P. multocida strains that cause fowl cholera in poultry typically belong to the serovars 1, 3, and 4. P. multocida causes atrophic rhinitis in pigs; it also can cause pneumonia or bovine respiratory disease in cattle. It may be responsible for mass mortality in antelopes (Peng et al., 2019).
P. multocida is the most common cause of wound infections in humans after dog or cat bites. The infection usually shows as soft tissue inflammation within 24 hours. High leukocyte and neutrophil counts are typically observed, leading to an inflammatory reaction at the infection site. It can also infect the respiratory tract, and is known to cause regional lymphadenopathy (swelling of the lymph nodes). In more serious cases, a bacteremia can result, causing an osteomyelitis or endocarditis. The bacteria may also cross the blood–brain barrier and cause meningitis. However, P. multocida can be effectively treated with β-lactam antibiotics, which inhibit cell wall synthesis. Vaccination against progressive atrophic rhinitis was developed using a purified recombinant derivative of the P. multocida toxin (PMT) (Nielsen et al., 1991).
- Kuhnert P; Christensen H, eds. (2008). Pasteurellaceae: Biology, Genomics and Molecular Aspects. Caister Academic Press. ISBN
- Nielsen JP, Foged NT, Sørensen V, Barfod K, Bording A, Petersen SK. Vaccination against progressive atrophic rhinitis with a recombinant Pasteurella multocida toxin derivative. Can J Vet Res. 1991 Apr;55(2):128-38.
- Peng Z, Wang X, Zhou R, Chen H, Wilson BA, Wu B. Pasteurella multocida: Genotypes and Genomics. Microbiol Mol Biol Rev. 2019 Sep 4;83(4):e00014-19.
Pasteurella multocida Antigens
The Native Antigen Company is pleased to provide recombinant P. multocida toxin for studies on the GTP trimer bound protein- dependent signaling pathway, and as a PMT antigen for immunological assays such as ELISA, western blotting and dot blotting.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Pasteurella multocida Antibodies
The Native Antigen Company has manufactured a rabbit polyclonal anti P. multocida toxin antibody for use alongside our toxin in the development of diagnostic assays and other applications.
Check out our FAQ section for answers to the most frequently asked questions about our website and company.